

Nebraska Medicaid Program Request for Prior Authorization of Payment Hereditary Angioedema (HAE)

If the following information is not complete, correct, or legible, the PA process can be delayed. *Please use one form per member.*

Member Information

LAST NAME: <input style="width: 100%; height: 20px;" type="text"/>	FIRST NAME: <input style="width: 100%; height: 20px;" type="text"/>
MEDICAID NUMBER: <input style="width: 100%; height: 20px;" type="text"/>	DATE OF BIRTH: <input style="width: 20px; height: 20px;" type="text"/> - <input style="width: 20px; height: 20px;" type="text"/> - <input style="width: 40px; height: 20px;" type="text"/>

Prescriber Information

LAST NAME: <input style="width: 100%; height: 20px;" type="text"/>	FIRST NAME: <input style="width: 100%; height: 20px;" type="text"/>
NPI NUMBER: <input style="width: 100%; height: 20px;" type="text"/>	DEA NUMBER: <input style="width: 100%; height: 20px;" type="text"/>
PHONE NUMBER: <input style="width: 20px; height: 20px;" type="text"/> - <input style="width: 20px; height: 20px;" type="text"/> - <input style="width: 40px; height: 20px;" type="text"/>	FAX NUMBER: <input style="width: 20px; height: 20px;" type="text"/> - <input style="width: 20px; height: 20px;" type="text"/> - <input style="width: 40px; height: 20px;" type="text"/>

Participating Pharmacy

NAME: <input style="width: 90%;" type="text"/>	REQUEST DATE <input style="width: 90%;" type="text"/>
PHONE NUMBER: <input style="width: 20px; height: 20px;" type="text"/> - <input style="width: 20px; height: 20px;" type="text"/> - <input style="width: 40px; height: 20px;" type="text"/>	FAX NUMBER: <input style="width: 20px; height: 20px;" type="text"/> - <input style="width: 20px; height: 20px;" type="text"/> - <input style="width: 40px; height: 20px;" type="text"/>

Please indicate which medication is being requested and complete the information below:

Preferred: <input type="checkbox"/> Berinert <input type="checkbox"/> Firazyr <input type="checkbox"/> Haegarda	Non-preferred: <input type="checkbox"/> Cinryze <input type="checkbox"/> icatibant acetate <input type="checkbox"/> Kalbitor <input type="checkbox"/> Ruconest <input type="checkbox"/> Takhzyro <input type="checkbox"/> Other: _____
---	---

Strength: _____ Dosing schedule: _____ Quantity per month: _____

For current PDL status, please visit: https://nebraska.fhsc.com/downloads/PDL/NE_PDL.pdf

1. Indicate reason for request: Angioedema prophylaxis treatment Treatment of acute hereditary angioedema
2. For HAE treatment, indicate HAE type: Type I Type II
3. If the patient is being prescribed the requested medication for a different diagnosis than above, document here (include ICD-10 diagnosis code): _____
4. Is the patient currently treated with the requested medication? Yes No
 If yes, when was treatment with the requested medication started? _____
5. For initial authorization, provide current labs of one of the following:
 C4 level below the lower limit normal defined by lab, or < 14 mg/dL
 C1-INH antigenic level below the lower limit of normal defined by lab, or < 19 mg/dL
 C1-INH functional level/percentage below the lower limit of normal defined by lab, or < 50%

(Form continued on next page)

**Nebraska Medicaid Program Request for Prior Authorization of Payment
Hereditary Angioedema (HAE)**

The following questions apply to requests for prophylaxis agents (Haegarda, Takhzyro, and Cinryze):

6. Does the patient have a history of two or more attacks monthly? Yes No
7. Will the requested medication be used for short term prophylaxis treatment (i.e., surgery, dental, or other medical procedures, etc.)? If so, provide details and date of event.

-
8. Has the patient had a trial and failure or contraindication to oral danazol? Yes No

9. Continuation or renewal of prophylactic therapy requires documentation of any or all of the following:

- Achieve and maintain at least a 50% reduction in number of HAE attacks
- Achieve and maintain at least a 30% reduction in number of HAE attacks
- Achieve and maintain at least a 60% reduction in days of swelling

10. Does the prescriber verify that the patient is NOT concurrently taking ACE inhibitors, NSAIDs, and estrogen-containing products? Yes No

If not, please explain:

Prescriber Signature (Required)

(By signing, the prescriber confirms that the above information is accurate and verifiable by patient records.)

Date